Read by QxMD icon Read

International Journal of MS Care

Francois Bethoux
No abstract text is available yet for this article.
September 2016: International Journal of MS Care
Robert Charlson, Joshua Herbert, Ilya Kister
Currently used classification schemes for multiple sclerosis (MS) have not taken into account disease severity, instead focusing on disease phenotype (ie, relapsing vs. progressive). In this article, we argue that disease severity adds a crucial dimension to the clinical picture and may help guide treatment decisions. We outline a practical, easy-to-implement, and comprehensive scheme for severity grading in MS put forward by our mentor, Professor Joseph Herbert. We believe that severity grading may help to better prognosticate individual disease course, formulate and test rational treatment algorithms, and enhance research efforts in MS...
September 2016: International Journal of MS Care
Freya Davies, Fiona Wood, Katherine E Brain, Michelle Edwards, Rhiannon Jones, Rachel Wallbank, Neil P Robertson, Adrian Edwards
Background: Identifying the transition from relapsing-remitting to secondary progressive multiple sclerosis (SPMS) can be challenging for clinicians. Little previous research has explored how professionals experience working with patients during this specific stage of the disease. We explored the experiences of a group of multidisciplinary professionals who support patients in the transition to SPMS to describe this stage from a professional perspective. Methods: This qualitative semistructured interview study included 11 professionals (medical, nursing, and allied health professionals; specialists and generalists) working with patients with MS in South Wales, United Kingdom...
September 2016: International Journal of MS Care
Matthew A Plow, Meghan Golding
Background: Evidence regarding inflammatory pathways, elevated cardiovascular risk, and negative effects of secondary conditions on disability progression provide a strong rationale for promoting multiple health behaviors in adults with multiple sclerosis (MS). However, many unanswered questions remain about the best ways to design multiple behavior change interventions for adults with MS. We sought to identify facilitators and barriers to engaging in multiple health behaviors (physical activity, nutrition, and sleep) and to gain further insights into how to develop multiple health behavior change interventions based on preferences of adults with MS...
September 2016: International Journal of MS Care
Paul N Taylor, Ingrid A Wilkinson Hart, Mansoor S Khan, Diana E M Slade-Sharman
Background: Footdrop is a significant problem in multiple sclerosis, reducing the safety and efficiency of walking. Functional electrical stimulation (FES) can produce dorsiflexion, correcting footdrop. The purpose of this retrospective analysis of clinical study data was to compare the effect of external and implanted FES devices for the correction of footdrop. Methods: External FES was used for a minimum of 6 months before implantation. Walking performance was assessed using 10-m walking speed, 3-minute walking distance, the Physiological Cost Index, and health- and device-related quality of life and device-use questionnaires...
September 2016: International Journal of MS Care
Stacey S Cofield, Robert J Fox, Tuula Tyry, Amber R Salter, Denise Campagnolo
Background: Physicians must weigh the benefits against the risk of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab, especially beyond 2 years. However, disability progression associated with switching therapies versus continuing natalizumab therapy after 2 years has not been fully evaluated. Methods: In this retrospective analysis using the NARCOMS Registry, disability progression (Patient-Determined Disease Steps [PDDS] scale) and physical health-related quality of life (HRQOL) worsening (12-item Short Form Health Status Survey Physical Component Score [SF-12 PCS]) were compared between participants switching to fingolimod (n = 50) or interferon beta (IFNβ)/glatiramer acetate (GA) (n = 71) therapy and those continuing natalizumab (n = 406) after 2 years or more of treatment (median follow-up: natalizumab, 4 years; fingolimod, 4...
September 2016: International Journal of MS Care
Lara A Pilutti, John E Paulseth, Carin Dove, Shucui Jiang, Michel P Rathbone, Audrey L Hicks
Background: There is evidence of the benefits of exercise training in multiple sclerosis (MS); however, few studies have been conducted in individuals with progressive MS and severe mobility impairment. A potential exercise rehabilitation approach is total-body recumbent stepper training (TBRST). We evaluated the safety and participant-reported experience of TBRST in people with progressive MS and compared the efficacy of TBRST with that of body weight-supported treadmill training (BWSTT) on outcomes of function, fatigue, and health-related quality of life (HRQOL)...
September 2016: International Journal of MS Care
Jordan Schultz, Cindy Weber, John Kamholz
No abstract text is available yet for this article.
September 2016: International Journal of MS Care
Francois Bethoux
No abstract text is available yet for this article.
July 2016: International Journal of MS Care
June Halper, Diego Centonze, Scott D Newsome, DeRen Huang, Christopher Robertson, Xiaojun You, Guido Sabatella, Vladimir Evilevitch, Leslie Leahy
BACKGROUND: Flu-like symptoms (FLSs) and injection-site reactions (ISRs) have been reported with interferon beta treatments for multiple sclerosis (MS). We sought to obtain consensus on the characteristics/management of FLSs/ISRs in patients with relapsing-remitting MS based on experiences from the randomized, placebo-controlled ADVANCE study of peginterferon beta-1a. METHODS: ADVANCE investigators with a predefined number of enrolled patients were eligible to participate in a consensus-generating exercise using a modified Delphi method...
July 2016: International Journal of MS Care
Sarah J Shoemaker, Alyssa Pozniak, Louise Hadden
BACKGROUND: Although hundreds of quality indicators (QIs) have been developed for various chronic conditions, QIs specific to multiple sclerosis (MS) care have only recently been developed. We sought to examine the extent to which the self-reported care of individuals with MS meets four recently developed MS QIs related to treatment of depression, spasticity, and fatigue and timely initiation of disease-modifying agents (DMAs) for relapsing MS. METHODS: Using the Sonya Slifka Study data, we examined the proportion of the MS population meeting four QIs (based on patient-reported data) in a sample of individuals with MS in 2007-2009...
July 2016: International Journal of MS Care
Holly A Parkerson, Melissa D Kehler, Donald Sharpe, Heather D Hadjistavropoulos
BACKGROUND: The Coping with Multiple Sclerosis Scale (CMSS) was developed to assess coping strategies specific to multiple sclerosis (MS). Despite its wide application in MS research, psychometric support for the CMSS remains limited to the initial factor analytic investigation by Pakenham in 2001. METHODS: The current investigation assessed the factor structure and construct validity of the CMSS. Participants with MS (N = 453) completed the CMSS, as well as measures of disability related to MS (Multiple Sclerosis Impact Scale), quality of life (World Health Organization Quality of Life Brief Scale), and anxiety and depression (Hospital Anxiety and Depression Scale)...
July 2016: International Journal of MS Care
Lauren B Strober, Allison Binder, Olga M Nikelshpur, Nancy Chiaravalloti, John DeLuca
BACKGROUND: Cognitive dysfunction affects approximately 43% to 70% of individuals with multiple sclerosis (MS) and is an important determinant of several functional outcomes in MS and quality of life. Brief neuropsychological test batteries have been developed specifically for use in MS and are widely used to aid clinicians in assessing levels of cognitive impairment in MS. Neuropsychologists and neurologists also frequently use briefer screening measures, such as the Perceived Deficits Questionnaire (PDQ), to assist in determining whether a more extensive neuropsychological evaluation is warranted...
July 2016: International Journal of MS Care
Richard A Sater, Mark Gudesblatt, Kiren Kresa-Reahl, David W Brandes, Pamela Sater
BACKGROUND: Patients with multiple sclerosis (MS) have higher rates of fatigue, mood disturbance, and cognitive impairments than healthy populations. Disease-modifying agents may affect sleep. Although patients taking natalizumab often show improvement in fatigue during the first year of therapy, the mechanism behind this effect is unknown. The aim of the NAPS-MS study was to investigate whether natalizumab affected objective measures of sleep as determined by polysomnography (PSG) and multiple sleep latency testing (MSLT) in patients with MS with fatigue or sleepiness initiating therapy...
July 2016: International Journal of MS Care
Theodore R Brown, Virginia I Simnad
BACKGROUND: Dalfampridine extended release (D-ER) is indicated to improve walking in people with multiple sclerosis (MS) as demonstrated by an increase in walking speed. This study assessed the effects of D-ER on accelerometer-based measures in people with MS, including intensity of walking and total amount of walking during daily activities. METHODS: In this double-blind placebo-controlled crossover study, people with MS-related walking difficulty were randomized (1:1) to receive 4 weeks of D-ER 10 mg twice daily and 4 weeks of placebo in either order separated by a 2-week washout...
July 2016: International Journal of MS Care
Pamela Newland, Louise Flick, Hong Xian, Florian P Thomas
BACKGROUND: The impact of tobacco on the multiple sclerosis (MS) disease process and symptoms is complex and not clearly understood. Tobacco may be used to self-treat some symptoms but also seems to intensify others. Studies to date have not characterized co-occurring symptoms (symptom patterns) and their association with tobacco use. METHODS: This study describes tobacco use in patients with relapsing-remitting MS and associated symptoms and symptom co-occurrences...
July 2016: International Journal of MS Care
Francois Bethoux
No abstract text is available yet for this article.
May 2016: International Journal of MS Care
Frank R Ernst, Jennifer Pocoski, Gary Cutter, David W Kaufman, Dirk Pleimes
BACKGROUND: We sought to compare mortality rates and related diagnoses in hospitalized patients with multiple sclerosis (MS), those with diabetes mellitus (DM), and the general hospitalized population (GHP). METHODS: Patients who died between 2007 and 2011 were identified in the US hospital-based Premier Healthcare Database. Demographic information was collected, mortality rates calculated, and principal diagnoses categorized. RESULTS: Of 55,152 unique patients with MS identified, 1518 died...
May 2016: International Journal of MS Care
William Meador, Amber R Salter, John R Rinker
BACKGROUND: Tremor affects 25% to 58% of patients with multiple sclerosis (MS) and is associated with poor prognosis and increased disability. MS-related tremor is difficult to treat, and data regarding patient-reported characterization and response to treatment are limited. We describe the symptomatic treatment of tremor in 508 enrollees in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry who self-reported tremor. METHODS: From 777 surveys sent to NARCOMS participants who indicated mild or greater tremor using the Tremor and Coordination Scale, we compiled data regarding disability, tremor severity, symptomatic medication use, and reported response to medications...
May 2016: International Journal of MS Care
Jonathan Calkwood, Timothy Vollmer, Robert J Fox, Ray Zhang, Mark Novas, Sarah I Sheikh, Vissia Viglietta
BACKGROUND: Delayed-release dimethyl fumarate (DMF; also known as gastroresistant DMF) is indicated for relapsing multiple sclerosis (MS). The objective of this study was to explore the safety and tolerability of DMF when administered with interferon beta (IFNβ) or glatiramer acetate (GA). METHODS: Patients with relapsing-remitting MS receiving established therapy with the same dose of IFNβ or GA for at least 12 months continued their prescribed therapy for 2 months (monotherapy period) and then received DMF 240 mg three times daily in addition to their prescribed MS therapy for 6 months (add-on therapy period)...
May 2016: International Journal of MS Care
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"